Kowa Pharmaceuticals

Kowa Pharmaceuticals America is the U.S. subsidiary of the privately held, multinational Kowa Company, Ltd., established in 2008 to lead the development and commercialization of Kowa's pharmaceutical products in the American market. The company leverages its parent's long history of R&D, particularly in cardiovascular and metabolic diseases, and is anchored by its flagship statin, LIVALO (pitavastatin). It operates through three main U.S. entities: Kowa Pharmaceuticals America (commercialization), Kowa Research Institute (clinical development), and Kowa Science Institute (early discovery). With a strong emphasis on compliance, training, and collaborative partnerships, the company aims to deliver effective treatments and enhance the value of its pharmaceutical portfolio.

Integrated U.S. commercialization and clinical development platform for small molecule therapeutics, leveraging parent company (Kowa Company, Ltd.) R&D and discovery capabilities.

Kowa competes in the crowded statin market and broader cardiovascular space against pharmaceutical giants like Pfizer, AstraZeneca, and Amgen. In ophthalmology, it would face competition from companies such as Regeneron, Roche, and Novartis. Its competitive edge lies in its focused commercialization, compliance focus, and the backing of a stable, diversified parent company.